Schrödinger, Inc. Reports Third Quarter 2026 Financial Results

Schrödinger reported third-quarter 2026 revenue of $64.5 million, above the FactSet consensus estimate of $47.7 million. Annual Contract Value grew 17%, and drug discovery revenue was $24 million. The company raised its full-year outlook for both ACV and drug discovery revenue, citing the strength of its integrated software and drug discovery business model.